Life sciences industry failing to adequately manage talent, RSA research finds

2 October 2011

While 90% of life sciences executives identify talent management as a key priority, over three quarters (77%) of their organizations are not delivering this in practice, operating without an active strategy in place. This is the headline finding of a global survey of over 550 life sciences senior managers carried out for executive search organization RSA.

Overall how companies manage talent is becoming less planned and more ad-hoc since RSA carried its previous research in 2010. Much of this is due to the continuing impact of market change and sluggish economic conditions. Two thirds of organizations (66%) have undergone a review or restructure in the last 18 months, with 78% reviewing headcount.

Not only do fewer organizations have a formal talent management strategy (up from 67% to 77%), they are also not using recognized processes when cutting jobs. Nearly eight in 10 (79%) admitted that they use no formal talent assessment exercises to identify which employees will face redundancy (up from 62% in 2010), while 38% don’t consider future demand for skills when making staff cuts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Biotechnology